Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461
Sherif S. Farag(Ain Shams University), Clara D. Bloomfield(North Shore University Hospital), Mazin Β. Qumsiyeh(University of Maryland, Baltimore), Kellie J. Archer(The Ohio State University), Richard M. Stone(Dana-Farber Cancer Institute), Prasad Koduru(University of Maryland, Baltimore), Richard A. Larson(Urbana University), Andrew J. Carroll(University of Alabama at Birmingham), Krzysztof Mrózek(The Ohio State University), Yi Ning(University of Maryland, Baltimore), Amy S. Ruppert(The University of Texas MD Anderson Cancer Center), James W. Vardiman(University of Chicago), Maria R. Baer(University of Maryland, Baltimore), Mark J. Pettenati, Robert J. Mayer(Applied Natural Sciences)
Cited by 332
Related Papers
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
|Blood|2016|10.2k
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k